Revelation Biosciences(REVB) - 2025 Q1 - Quarterly Results

Financial Results Announcement This section details Revelation Biosciences' Q1 2025 financial performance and key corporate developments Overview and Corporate Highlights Revelation Biosciences reported Q1 2025 financial results, detailing pipeline progress and cash position - CEO James Rolke highlighted continued pipeline expansion, collaboration with Vanderbilt in severe burns, and anticipation of Phase 1b PRIME clinical study topline data this summer[2] | Metric | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Cash and cash equivalents | $3.7 million | $6.5 million | - The decrease in cash and cash equivalents was primarily due to cash used for operating activities. Current cash and cash equivalents are sufficient to fund operations through June 2025[2] Key Financial Summary Revelation Biosciences reported a Q1 2025 net loss of $2.1 million, an improvement from prior year, with consistent operating cash usage | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | Change (YoY) | | :-------------------------------- | :-------------------------------- | :-------------------------------- | :----------- | | Net loss | $(2.1) million | $(2.7) million | +$0.6 million | | Basic and diluted net loss per share | $(2.11) | $(39.37) | +$37.26 | | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net cash used for operating activities | $2.8 million | $2.8 million | Product and Company Information This section outlines Gemini, the company's proprietary product, and Revelation Biosciences' corporate profile and recent developments About Gemini (Product Overview) Gemini is Revelation's proprietary PHAD® formulation, an intravenously administered product with positive Phase 1 data for inflammation reduction - Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) that reduces inflammation damage by reprogramming the innate immune system[4] - Positive Phase 1 clinical data for Gemini met the primary safety endpoint and demonstrated statistically significant pharmacodynamic activity, observed through expected changes in multiple biomarkers including upregulation of IL-10[4] - Gemini is being developed for multiple indications, including as a pretreatment for acute kidney injury (GEMINI-AKI), post-surgical infection (GEMINI-PSI), and as a potential treatment for chronic kidney disease (GEMINI-CKD)[5] About Revelation Biosciences, Inc. (Company Overview) Revelation Biosciences is a clinical-stage life sciences company focused on trained immunity with its proprietary Gemini formulation - Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini[8] - Recent corporate highlights include: * Announced a new indication for Gemini in severe burn patients * Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells * Completed dosing of the first patient in the PRIME Phase 1b Clinical Study of Gemini in CKD Patients[7] Financial Statements This section presents the company's consolidated statements of operations and balance sheets for the specified periods Consolidated Statements of Operations The company reported a Q1 2025 net loss of $(2,051,085), an improvement from prior year, primarily due to other income | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | Change (YoY) | | :-------------------------------- | :-------------------------------- | :-------------------------------- | :----------- | | Research and development | $858,830 | $717,582 | +$141,248 | | General and administrative | $1,236,157 | $1,184,556 | +$51,601 | | Total operating expenses | $2,094,987 | $1,902,138 | +$192,849 | | Loss from operations | $(2,094,987) | $(1,902,138) | -$192,849 | | Total other income (expense), net | $43,902 | $(779,295) | +$823,197 | | Net loss | $(2,051,085) | $(2,681,433) | +$630,348 | | Net loss per share, basic and diluted | $(2.11) | $(39.37) | +$37.26 | | Weighted-average shares used to compute net loss per share, basic and diluted | 971,313 | 68,115 | +903,198 | Consolidated Balance Sheets As of March 31, 2025, total assets decreased to $3.97 million, driven by lower cash, with a significant reduction in total liabilities | Metric | March 31, 2025 | December 31, 2024 | Change | | :-------------------------------- | :------------- | :---------------- | :----- | | Cash and cash equivalents | $3,704,611 | $6,499,018 | -$2,794,407 | | Prepaid expenses and other current assets | $223,270 | $66,699 | +$156,571 | | Total current assets | $3,927,881 | $6,565,717 | -$2,637,836 | | Total assets | $3,970,271 | $6,622,049 | -$2,651,778 | | Accounts payable | $625,058 | $783,621 | -$158,563 | | Accrued expenses | $463,632 | $1,127,800 | -$664,168 | | Warrant liability | $829 | $2,246 | -$1,417 | | Total current liabilities | $1,089,519 | $1,913,667 | -$824,148 | | Total stockholders' equity | $2,880,752 | $4,708,382 | -$1,827,630 | Additional Information This section includes important disclaimers regarding forward-looking statements and company contact information Forward-Looking Statements This section provides a standard disclaimer on forward-looking statements, outlining inherent risks and uncertainties that may affect actual results - Forward-looking statements are based on management's expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from those anticipated[10] - Key risks include the ability to meet financial and strategic goals, grow profitably, retain key employees, successfully develop product candidates, complete planned clinical studies, manage adverse safety events, navigate regulatory changes, and the expected duration over which balances will fund operations[10] Company Contacts Contact information for investor relations and the Chief Financial Officer of Revelation Biosciences Inc is provided - Contact information is provided for Mike Porter (Investor Relations, Porter LeVay & Rose Inc.) and Chester S. Zygmont, III (Chief Financial Officer, Revelation Biosciences Inc.)[15]